Eli Lilly Q1 2026: Zepbound sales surge 80% to $4.16B

Eli Lilly reported strong first-quarter 2026 earnings, driven by soaring demand for its weight loss drugs. U.S. sales of Zepbound, the company's obesity treatment, reached $4.16 billion, an 80% increase year-over-year. Sales of Mounjaro, Lilly's diabetes drug, more than doubled compared to the same period last year. The results underscore the booming market for GLP-1 receptor agonists, which have become blockbuster therapies for weight management and metabolic conditions. Lilly raised its full-year revenue guidance, reflecting continued optimism about the growth trajectory of these drugs. The company faces competition from Novo Nordisk's Wegovy and Ozempic but maintains a strong market position with its dual-indication portfolio.